WO2014076680A1 - Solid dosage form comprising micronized cytisine - Google Patents

Solid dosage form comprising micronized cytisine Download PDF

Info

Publication number
WO2014076680A1
WO2014076680A1 PCT/IB2013/060230 IB2013060230W WO2014076680A1 WO 2014076680 A1 WO2014076680 A1 WO 2014076680A1 IB 2013060230 W IB2013060230 W IB 2013060230W WO 2014076680 A1 WO2014076680 A1 WO 2014076680A1
Authority
WO
WIPO (PCT)
Prior art keywords
cytisine
microcrystalline cellulose
active ingredient
present
micronised
Prior art date
Application number
PCT/IB2013/060230
Other languages
French (fr)
Inventor
Hanna WAHL
Marek DĄBROWA
Piotr KULAZIŃSKI
Original Assignee
Aflofarm Farmacja Polska Spolka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50730669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014076680(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to RS20200483A priority Critical patent/RS60249B1/en
Priority to DK13826599.6T priority patent/DK2919761T3/en
Priority to LTEP13826599.6T priority patent/LT2919761T/en
Priority to AU2013346363A priority patent/AU2013346363B2/en
Priority to EP13826599.6A priority patent/EP2919761B1/en
Application filed by Aflofarm Farmacja Polska Spolka Z Ograniczona Odpowiedzialnoscia filed Critical Aflofarm Farmacja Polska Spolka Z Ograniczona Odpowiedzialnoscia
Priority to NZ708199A priority patent/NZ708199A/en
Priority to SI201331712T priority patent/SI2919761T1/en
Priority to ES13826599T priority patent/ES2793527T3/en
Priority to US14/443,584 priority patent/US9387172B2/en
Publication of WO2014076680A1 publication Critical patent/WO2014076680A1/en
Priority to HRP20200642TT priority patent/HRP20200642T1/en
Priority to CY20201100355T priority patent/CY1122947T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Definitions

  • the composition of the core prevents its use in patients with hereditary galactose intolerance, lactase insufficiency (Lapp-type) nor the poor galactose-lactose absorption syndrome, and may cause tablet instability due to the presence of a carboxyl group in the lactose molecule, which is not completely inert chemically and may lead to a Maillard reaction. This results in a brownish discoloration of the tablet.
  • the method of producing the tablet also entails many complex physical processes/phenomena which may have a deleterious effect on the medicinal product.
  • the capsule mass (composition according to Table 1, Example No. 1) was prepared using two alternative active ingredient grain sizes as well as different amounts of cytisine.
  • Sample P4al was prepared using an active ingredient grain size of 100% ⁇ 80mesch (180pm), whereas sample P4a2 was prepared using micronised active ingredient (100% particles below 10 um) ; according to the present invention.
  • Sample P4a3 was prepared according to the composition and technology described in Table 1, Example No. 1 with the exception that the amount of active ingredient was 0.38mg/380mg and analogously in sample P4a4 except that the amount of active ingredient was 19mg/380mg of capsule mass; the remaining substances as well as the method of preparing were according to the present invention.
  • the content of the active ingredient in samples of capsule mass collected from different parts of the mixer is illustrated in Table 4al.
  • the determined composition facilitates the appropriate proportions of ancillary substances as well as their sufficient dispersal in the case of ancillary substances present in largest quantities.
  • composition according to the composition of the present invention (Example No. 1) except that we used microcrystalline cellulose of standard grain size (average grains of 100 m) ,
  • composition according to the composition of the present invention (Example No. 1) except that we used corn starch with a standard (from 25 m to 32 m) grain size
  • composition according to the composition of the present invention (Example No. 1) except that we used the following amount of microcrystalline cellulose - 228mg / 380mg and corn starch 152mg / 380mg.
  • compositions as well as the technological process ensure the rapid dissolution rate of cytisine from the final drug form.
  • the comparison product used was Tabex s: 4041011.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject of the present invention is solid dosage form containing cytisine and ancillary substances characterised in that it contains from 0.1% to 5% micronised cytisine, wherein all molecules have a diameter less than from 10 μπι, corn starch from 40% to 60%, preferably 99,9% particles sized from 5 μπι to 25 μπι, macrocrystalline cellulose in an amount from 40% to 60%, preferably the particle size is: 99% below 38μπι, wherein the mass ratio of ancillary substances to the active ingredient is from 1:19 to 1:999 and is in the form of a hard capsule as well as a method of obtaining it.

Description

SOLID DOSAGE FORM COMPRISING MICRONIZED CYTISINE
The subject of the present invention is a solid dosage form containing micronised cytisine as well as a method of producing it. The present invention is useful in pharmacy as well as medicine.
There is a medicinal preparation to ease quitting smoking in the form of coated tablet with the trade name Tabex which contains 1.5 mg cytisine per tablet and ancillary substances: calcium bicarbonate, lactose, wheat starch, Avicel PH 101, powdered talcum, magnesium stearate and a coating. The tablet core composition does not ensure the stability of the coated tablet, nor does it give it sufficient mechanical resistance nor the necessary separation of the active ingredient. The resulting tablets have a low mechanical resistance and resistance to abrasion and to not fulfill the requirements set out in the European Pharamcopeia relating to the even dispersion and solubility of cytisine. Polish patent PL1586320 discloses a tablet containing cytisine, whose composition facilitates the homogenous dispersion of the active ingredient throughout the tablet, ensuring the high solubility of cytisine. In addition to cytisine, this product contains the following ancillary substances: lactose monohydrate, macrocrystalline cellulose, talcum, magnesium stearate as well as an Opadry II coating, in the form of a tablet. Through the presence of lactose, the composition of the core prevents its use in patients with hereditary galactose intolerance, lactase insufficiency (Lapp-type) nor the poor galactose-lactose absorption syndrome, and may cause tablet instability due to the presence of a carboxyl group in the lactose molecule, which is not completely inert chemically and may lead to a Maillard reaction. This results in a brownish discoloration of the tablet. The method of producing the tablet also entails many complex physical processes/phenomena which may have a deleterious effect on the medicinal product. One of these phenomena is a high temperature during the tableting process which has a negative effect on cytisine stability during the process, which is evidenced by the initial results of contaminant content in the product encompassed by the above patent (PL1586320) . Thus, there is still a need to obtain a pharmaceutical composition containing cytisine that eliminates the risk of the deleterious effects of the Maillard reaction, enclosed in a drug form that negates the negative effect of triturating forces on the tablet's mechanical stability, which additionally ensure a high degree of cytisine solubility as well as its stability and homogenous dispersion, which will be available to hereditary galactose intolerance. Unexpectedly, these problems have been solved by the present invention.
The first subject of the present invention is a solid dosage form containing cytisine and ancillary substances characterised in that it contains from 0.1% to 5% micronised cytisine, wherein all molecules have a diameter less than from 10 μπι, corn starch from 40% to 60% , preferably 99,9% molecules sized from 5 m to 25 μπι, microcrystalline cellulose in an amount from 40% to 60%, preferably the molecular size is: 99% below 38μηι, wherein the mass ratio of ancillary to active substances is from 1:19 to 1:999 and is in the form of a hard capsule. Preferably, a solid dosage form according to the present invention contains coloidal silica in the amount of 0.4% as well as magnesium stearate and the capsule contains gelatine, titanium dioxide and indigotine.
The second subject of the present invention is a method of obtaining a hard capsule containing cytisine defined in the first subject of the present invention characterised in that it encompasses a) mixing micronised cytisine with a portion, preferably from 0.70% to 0.90%, of the microcrystalline cellulose necessary for the whole process,
b) mixing the formed mixture from stage a) with a portion, preferably from 12% to 16% the remaining quantity of microcrystalline cellulose necessary for the whole process c) mixing the formed mixture from stage b) with the remaining quantity of microcrystalline cellulose necessary for the whole process as well as then the remaining ancillary substances to homogeneity
d) encapsulation.
Equally preferably, a method according to the present invention is characterised in that in stage a) 0.79% are mixed and in stage b) 14.4% of the micronised microcrystalline cellulose.
The nature of the present invention is based on the formation of a homogenous mass of powdered substances (capsule mass) , dosed into hard gelatine capsules containing a homogenously dispersed active ingredient, prepared without the use of increased moisture and temperature which ensures cytisine stability throughout the technological process. Additionally, the formulation without the use of lactose ensures therapeutic access to a broader group of recipients and decreases the risk of product discolouration due to the Maillard reaction. We produced a capsule mass according to the present invention dosed into hard gelatine capsules with the following content of the active ingredient (Table 1) .
Example No. 1 A method of obtaining capsules according to the present invention
A product being the subject of the present invention, whose preferable embodiment is shown in Table 1, was prepared according to the following production technology:
An appropriate mass of micronised cytisine was mixed with 0.79% the necessary amount of microcrystalline cellulose (of appropriate grain size) , then added to a container which contained 14,4% of the necessary amount of microcrystalline cellulose of appropriate grain size, and the entirety was mixed.
The container was supplemented with the remaining amount of microcrystalline cellulose (of appropriate grain size) as well as a mixture of cytisine with microcrystalline cellulose, mixed and then added to corn starch (of appropriate grain size) , colloidal silica and magnesium stearate. The container was placed on a mixing column and the contents were mixed. The capsule mass was dosed into hard gelatine capsules.
The requirements relating to ingredient dispersal were as follows :
- cytisine: 100% below 10 pm,
- microcrystalline cellulose: 99% below 38 m
- corn starch: 99,9% molecules in the range of 5 μηα do 25 um
Table 1 - Composition of the subject product of the present invention:
Figure imgf000006_0001
capsule mass for dosing into hard gelatine capsules wherein the active ingredient contaminant content is below the level of detection due to the experimentally selected pharmaceutical composition, the appropriate dispersion of the composition components and the production technology used.
The selection of the appropriate composition in experimentally derived ratios and the use of the medicinal substance, microcrystalline cellulose and corn starch with an appropriate, experimentally derived grain size as well as the above described technology for forming the capsule mass enabled the hard capsule to attain a homogenous distribution of the active ingredient in the form of a drug, with out the use of production stages connected with increased temperature and moisture.
Additionally, the use of corn starch, microcrystalline cellulose as well as colloidal silica ensures protection of the active ingredient against the deleterious effects of the external environment during the technological process (Example No. 2) and the formulation not makings use of lactose increases the applicability of the preparation and prevents discolouration via the Maillard reaction. Acceptance criteria of the present invention were: a low level (below the detection threshold) of active ingredient contaminants of the final drug form at the end of the technological process (experimental description illustrated in Example No. 3) , homogeneity of the active ingredient dispersion in the capsule mass (experimental description given in Example No. 4.) as well as a high solubility of cytisine from the complete drug form (bioavailability) of cytisine (experimental description given in Example No. 5.)
Example No. 2
Cytisine stability depending on the ancillary substances used during stability stress testing.
The disclosed composition of the present invention ensures the best active ingredient stability during stress testing. We determined acceptance criteria: lowest degree of active ingredient contamination during the storage of the active ingredient under stress conditions: temp. 60 °C and time - two weeks. We prepared mixtures of substances of the following compositions :
2a: composition according to the composition of the present invention (Example No. 1)
2b: analogous composition to 2a except that instead of corn starch we used potato starch
2c: analogous composition to 2a except that instead of corn starch we used potato starch, and the microcrystalline cellulose was replaced with lactose monohydrate;
2d: analogous composition to 2a except that instead of microcrystalline cellulose we used lactose monohydrate.
2e: analogous composition to 2a except that instead of corn starch we used lactose monohydrate, and the mass ratio of lactose to microcrystalline cellulose was 1:2 (analogously as in Example 1 of patent PL1586320) . Unexpectedly it turned out that there are significant differences in the contaminant levels of the active ingredient at the end of the test, these results are shown in Table 2a.
Table 2a: Contaminant content of the active ingredient the end of the stability stress test.
Figure imgf000008_0001
The best protection for the active ingredient during the stress test (lowest contaminant growth) is afforded by the composition being the subject of the present invention (Table 1 ; sample la) . Unexpectedly it turned out that in addition to the lowest summary contaminant level in comparison to the other combinations, only in this case we observed the presence of a single contaminant.
Example No. 3
Cytisine stability throughout the technological process The disclosed technical process ensures the lowest (below the detection threshold) contaminant level of the active ingredient in the complete drug. We established an acceptance criterion: contaminant level below the limit of detection (LOD)
The capsule mass (composition according to Table 1, Example No. 1) was prepared using two alternative methods; the first (P3a) encompassed granulation and drying at 50°C. The second method of preparing the capsule mass (P3b) described in the nature of this patent did not require the use of solvents, nor of high temperatures.
We obtained the following results of active ingredient contaminant levels Table 3a.
Table 3a. Contaminant content of the active ingredient in the complete drug form during the experimental procedures
Figure imgf000009_0001
The use of the capsule mass preparation technology described in the nature of the present invention significantly affects the decrease of active ingredient contamination in comparison to wet granulation.
Example No. 4
Homogeneity of cytisine dispersion in the capsule mass.
The disclosed composition and technological process facilitate the production of a capsule mass homogenous in terms of active ingredient content, dosed into gelatine capsules via a hard capsule at a level below 3%
This part of the present invention entailed a need to perform the following experiments: 4a) Determination of the amount as well as size of the grains of the active ingredient.
The capsule mass (composition according to Table 1, Example No. 1) was prepared using two alternative active ingredient grain sizes as well as different amounts of cytisine. Sample P4al was prepared using an active ingredient grain size of 100% < 80mesch (180pm), whereas sample P4a2 was prepared using micronised active ingredient (100% particles below 10 um) ; according to the present invention. Sample P4a3 was prepared according to the composition and technology described in Table 1, Example No. 1 with the exception that the amount of active ingredient was 0.38mg/380mg and analogously in sample P4a4 except that the amount of active ingredient was 19mg/380mg of capsule mass; the remaining substances as well as the method of preparing were according to the present invention. The content of the active ingredient in samples of capsule mass collected from different parts of the mixer (three samples each from three levels of the capsule mass, three weigh-offs of 380mg were prepared from each sample) is illustrated in Table 4al.
Table 4al Cytisine content in samples collected after mixing the capsule mass.
Figure imgf000010_0001
Figure imgf000011_0001
X - average
S2 - standard deviation
RSD3 - relative standard deviation The sample prepared using micronised cytisine is characterised by a high homogeneity of the active ingredient therein, in contrast to the sample prepared using standard-sized cytisine grains. 4b) Determination of the appropriate ancillary substance proportions
The determined composition facilitates the appropriate proportions of ancillary substances as well as their sufficient dispersal in the case of ancillary substances present in largest quantities.
During the experiment we tested formulations of capsule masses containing different proportions and grain sizes of microcrystalline cellulose as well as corn starch:
4bl: composition according to the composition of the present invention (Example No. 1) except that we used microcrystalline cellulose of standard grain size (average grains of 100 m) ,
4b2: composition according to the composition of the present invention (Example No. 1) except that we used corn starch with a standard (from 25 m to 32 m) grain size
4b3 composition according to the composition of the present invention (Example No. 1) except that we used the following amount of microcrystalline cellulose - 152mg / 380mg and corn starch 228mg / 380mg
4b4 composition according to the composition of the present invention (Example No. 1) except that we used the following amount of microcrystalline cellulose - 228mg / 380mg and corn starch 152mg / 380mg.
It turned out that the samples (4bl and 4b2) prepared using grains sizes different from those according to the present invention did not yield satisfactory results , whereas the remaining sample results as in the present invention (4b3 and 4b4) gave results within approved acceptance criteria. This is shown by the results shown in Table 4b: Table 4b Cytisine content in the final drug form.
Figure imgf000013_0001
where :
X1 - average
S2 - standard deviation
RSD3 - relative standard deviation
Example No. 5
Cytisine solubility from the final drug form.
The disclosed composition the present invention as well as the technological process ensure the rapid dissolution rate of cytisine from the final drug form. The comparison product used was Tabex s: 4041011.
The designated acceptance criterion was the active ingredient dissolution time from the final drug form in an acceptor fluid, which was O.lmol/1 hydrochloric acid imitating the conditions found in the human stomach.
We loaded the bottom of a beaker containing O.lmol/1 hydrochloric acid with a single tablet of Tabex, and in another a single gelatine capsule prepared according to the composition and technology described in Example No. 1 (P5) . During mixing, we collected samples of the acceptor solution at the following time points: after 5 min., 7.5min, lO.Omin as well as 12.5min. The cytisine content in the acquired samples is illustrated in Table 5a.
Table 5a Cytisine content in the acceptor solution depending on time.
Figure imgf000015_0001
Unexpectedly it turned out that cytisine from the final drug form described in the present invention dissolves faster than from a tablet defined in PL1586320 and present on the market.

Claims

Claims
1. A solid dosage form containing cytisine and ancillary substances, characterised in that it contains from 0.1% to 5% micronised cytisine, wherein all molecules have a diameter less than ΙΟμιη, corn starch from 40% to 60%, preferably 99,9% particles sized from 5 um to 25 um, microcrystalline cellulose in an amount from 40% to 60%, preferably the particle size is: 99% below 38um, wherein the mass ratio of ancillary substances to the active ingredient is from 1:19 to 1:999 and is in the form of a hard capsule.
2. A solid dosage form according to Claim 1 characterised in that it contains coloidal silica in the amount of 0.4% as well as magnesium stearate and the capsule contains gelatine, titanium dioxide and indigotine.
3. A method of obtaining a hard capsule containing cytisine, defined in Claim 1 or 2 characterised in that it encompasses: a) mixing micronised cytisine with a portion, preferably from 0.70% to 0.90%, of the microcrystalline cellulose necessary for the whole process,
b) mixing the formed mixture from stage a) with a portion, preferably from 12% to 16% of the remaining quantity of microcrystalline cellulose necessary for the whole process, c) mixing the mixture from stage b) with the remaining quantity microcrystalline cellulose necessary for the whole process as well as the remaining ancillary substances to homogeneity;
d) encapsulation
4. A method according to Claim 3 characterised in that in stage a) 0.79% and in stage b) 14,4 % of the micronised microcrystalline cellulose is mixed.
PCT/IB2013/060230 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine WO2014076680A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US14/443,584 US9387172B2 (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine and its production method
DK13826599.6T DK2919761T3 (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine
LTEP13826599.6T LT2919761T (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine
AU2013346363A AU2013346363B2 (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine
EP13826599.6A EP2919761B1 (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine
RS20200483A RS60249B1 (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine
NZ708199A NZ708199A (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine
SI201331712T SI2919761T1 (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine
ES13826599T ES2793527T3 (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine
HRP20200642TT HRP20200642T1 (en) 2012-11-19 2020-04-15 Solid dosage form comprising micronized cytisine
CY20201100355T CY1122947T1 (en) 2012-11-19 2020-04-15 SOLID DOSAGE FORM CONTAINING MICRONIZED CYTICIN

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL401676A PL220354B1 (en) 2012-11-19 2012-11-19 Solid dosage form comprising micronized cytisine, and a production method thereof
PLPL401676 2012-11-19

Publications (1)

Publication Number Publication Date
WO2014076680A1 true WO2014076680A1 (en) 2014-05-22

Family

ID=50730669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/060230 WO2014076680A1 (en) 2012-11-19 2013-11-19 Solid dosage form comprising micronized cytisine

Country Status (16)

Country Link
US (1) US9387172B2 (en)
EP (1) EP2919761B1 (en)
AU (1) AU2013346363B2 (en)
CL (1) CL2015001343A1 (en)
CY (1) CY1122947T1 (en)
DK (1) DK2919761T3 (en)
ES (1) ES2793527T3 (en)
HR (1) HRP20200642T1 (en)
HU (1) HUE048912T2 (en)
LT (1) LT2919761T (en)
NZ (1) NZ708199A (en)
PL (1) PL220354B1 (en)
PT (1) PT2919761T (en)
RS (1) RS60249B1 (en)
SI (1) SI2919761T1 (en)
WO (1) WO2014076680A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2957280A1 (en) * 2014-06-18 2015-12-23 Pharmacia Polonica Spolka z Ograniczona Odpowiedzialnoscia Solid pharmaceutical composition of cytisine and process for preparation thereof
WO2017134468A1 (en) * 2016-02-05 2017-08-10 Achieve Pharma Uk Limited Succinate salt of cytisine and use thereof
WO2019020993A1 (en) 2017-07-24 2019-01-31 Achieve Pharma Uk Limited Cytisine salts
EP3598968A1 (en) 2018-07-23 2020-01-29 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
WO2020206511A1 (en) * 2019-04-12 2020-10-15 Sopharma Ad Oral pharmaceutical composition with a plant alkaloid for treatment of dependencies

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL444090A1 (en) * 2023-03-16 2024-09-23 Uniwersytet Rzeszowski Polymer compositions containing cytisine and method of producing it

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586320A1 (en) 2004-04-16 2005-10-19 Sopharma AD Cytisine containing solid dosage form
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
EP2233134A1 (en) * 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003984A (en) 2008-10-14 2011-05-10 Mcneil Ab Multi portion intra-oral dosage form and use thereof.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586320A1 (en) 2004-04-16 2005-10-19 Sopharma AD Cytisine containing solid dosage form
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
EP2233134A1 (en) * 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2957280A1 (en) * 2014-06-18 2015-12-23 Pharmacia Polonica Spolka z Ograniczona Odpowiedzialnoscia Solid pharmaceutical composition of cytisine and process for preparation thereof
EP2957280B1 (en) 2014-06-18 2019-04-17 Bonteque Consulting LTD Solid pharmaceutical composition of cytisine and process for preparation thereof
WO2017134468A1 (en) * 2016-02-05 2017-08-10 Achieve Pharma Uk Limited Succinate salt of cytisine and use thereof
CN108883101A (en) * 2016-02-05 2018-11-23 英国雅琪制药有限公司 Succinate of eulexine and application thereof
EP4265298A3 (en) * 2016-02-05 2024-01-10 Achieve Pharma UK Limited Salt
US10300050B2 (en) 2016-02-05 2019-05-28 Achieve Pharma Uk Limited Succinate salt of cytisine and use thereof
EP4265298A2 (en) 2016-02-05 2023-10-25 Achieve Pharma UK Limited Salt
AU2017215300B2 (en) * 2016-02-05 2022-03-03 Achieve Pharma Uk Limited Succinate salt of cytisine and use thereof
CN111278826A (en) * 2017-07-24 2020-06-12 英国雅琪制药有限公司 Wild indigo base salt
WO2019020993A1 (en) 2017-07-24 2019-01-31 Achieve Pharma Uk Limited Cytisine salts
WO2020020711A3 (en) * 2018-07-23 2020-06-11 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
WO2020020711A2 (en) 2018-07-23 2020-01-30 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
EP3598968A1 (en) 2018-07-23 2020-01-29 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
WO2020206511A1 (en) * 2019-04-12 2020-10-15 Sopharma Ad Oral pharmaceutical composition with a plant alkaloid for treatment of dependencies
CN113194930A (en) * 2019-04-12 2021-07-30 索非药剂有限公司 Oral pharmaceutical composition containing plant alkaloids for treating dependence

Also Published As

Publication number Publication date
RS60249B1 (en) 2020-06-30
US9387172B2 (en) 2016-07-12
HRP20200642T1 (en) 2020-09-04
CY1122947T1 (en) 2021-10-29
AU2013346363A1 (en) 2015-06-11
NZ708199A (en) 2018-10-26
DK2919761T3 (en) 2020-11-02
HUE048912T2 (en) 2020-08-28
PL220354B1 (en) 2015-10-30
EP2919761B1 (en) 2020-01-15
PT2919761T (en) 2020-05-18
AU2013346363B2 (en) 2018-08-09
LT2919761T (en) 2020-05-25
CL2015001343A1 (en) 2015-10-23
PL401676A1 (en) 2014-05-26
ES2793527T3 (en) 2020-11-16
SI2919761T1 (en) 2020-08-31
US20150342884A1 (en) 2015-12-03
EP2919761A1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
US9387172B2 (en) Solid dosage form comprising micronized cytisine and its production method
EA028179B1 (en) Solid dosage forms of bendamustine
Ahmed et al. Miconazole nitrate oral disintegrating tablets: in vivo performance and stability study
WO2019149917A1 (en) A pharmaceutical composition comprising metamizole, drotaverine, and caffeine
WO2011074660A1 (en) Elution-stabilized preparation
US20090209587A1 (en) Repaglinide formulations
CN103717209A (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions
EP2957280B1 (en) Solid pharmaceutical composition of cytisine and process for preparation thereof
JP6880000B2 (en) Film-coated tablets with excellent chemical stability of the active ingredient
RU2462248C2 (en) Stable pharmaceutical composition containing water-soluble vinflunine salt
HU227142B1 (en) Capsule of improved release containing fluconazole
JP6367042B2 (en) Pharmaceutical composition comprising voriconazole
KR20160002177A (en) Pharmaceutical composition comprising oseltamivir free base
JP5774308B2 (en) Stable pharmaceutical composition of water-soluble vinorelbine salt
KR102102462B1 (en) Pharmaceutical composition comprising oseltamivir free base
CN105902564A (en) Pharmaceutical composition for treating hypertension and preparation method thereof
Aboutaleb et al. Formulation of domperidone in gastro-retentive floating tablets
CN114831943B (en) Preparation method of pharmaceutical composition
CN104586807B (en) Sustained release preparation for treating Alzheimer&#39;s disease and preparation method thereof
AU2019308862B2 (en) Solid pharmaceutical cytisine composition
Gul et al. Formulation of improved norfloxacin HCl tablets: quality control assessment and comparison study of acidic and basic form of norfloxacin in tablet formulation
CN104116719B (en) A kind of huperzine A is adjusted and is released tablet composition and preparation method thereof
RU2266106C1 (en) Method for preparing antibacterial agent
Assefa et al. Formulation, Optimization and
Suryawanshi et al. FAST DISPERSING TABLETS REVIEW

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13826599

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14443584

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013826599

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013346363

Country of ref document: AU

Date of ref document: 20131119

Kind code of ref document: A